Vir Biotechnology (VIR) Common Equity (2018 - 2026)

Vir Biotechnology has disclosed Common Equity across 9 years of filings, most recently posting $812.8 million for Q1 2026.

• Common Equity for Q1 2026 came in at $812.8 million, down 22.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $812.8 million (down 22.14% YoY), and the FY2025 annual result was $765.3 million, down 33.48% from the prior year.
• Common Equity came in at $812.8 million for Q1 2026 at Vir Biotechnology, up from $765.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 billion in Q3 2022 to a low of $765.3 million in Q4 2025.
• The 5-year median for Common Equity is $1.5 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Common Equity surged 207.4% in 2022 and tumbled 35.84% in 2025, its largest moves.
• Vir Biotechnology's Common Equity stood at $2.1 billion in 2022, then decreased by 23.47% to $1.6 billion in 2023, then retreated by 27.66% to $1.2 billion in 2024, then plunged by 33.48% to $765.3 million in 2025, then gained by 6.21% to $812.8 million in 2026.
• The last three Common Equity figures came in at $812.8 million (Q1 2026), $765.3 million (Q4 2025), and $796.1 million (Q3 2025), per Business Quant data.